ATE502640T1 - Allosterische a3-adenosin-rezeptormodulatoren - Google Patents
Allosterische a3-adenosin-rezeptormodulatorenInfo
- Publication number
- ATE502640T1 ATE502640T1 AT07763034T AT07763034T ATE502640T1 AT E502640 T1 ATE502640 T1 AT E502640T1 AT 07763034 T AT07763034 T AT 07763034T AT 07763034 T AT07763034 T AT 07763034T AT E502640 T1 ATE502640 T1 AT E502640T1
- Authority
- AT
- Austria
- Prior art keywords
- adenosine receptor
- a3rm
- a3ar
- allosteric
- subject
- Prior art date
Links
- 101150046889 ADORA3 gene Proteins 0.000 title abstract 6
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76214106P | 2006-01-26 | 2006-01-26 | |
| PCT/US2007/001930 WO2007089507A1 (en) | 2006-01-26 | 2007-01-25 | A3 adenosine receptor allosteric modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE502640T1 true ATE502640T1 (de) | 2011-04-15 |
Family
ID=38116104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07763034T ATE502640T1 (de) | 2006-01-26 | 2007-01-25 | Allosterische a3-adenosin-rezeptormodulatoren |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8420664B2 (de) |
| EP (1) | EP1983990B1 (de) |
| JP (2) | JP5414277B2 (de) |
| KR (1) | KR101383228B1 (de) |
| CN (1) | CN101410114B (de) |
| AT (1) | ATE502640T1 (de) |
| DE (1) | DE602007013359D1 (de) |
| DK (1) | DK1983990T3 (de) |
| ES (1) | ES2360632T3 (de) |
| WO (1) | WO2007089507A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| DK1983990T3 (da) | 2006-01-26 | 2011-07-11 | Us Gov Health & Human Serv | Allosteriske A3-adenosin-receptormodulatorer |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| US7906518B2 (en) * | 2006-06-27 | 2011-03-15 | Cbt Development Limited | Therapeutic compounds |
| EP1889846A1 (de) | 2006-07-13 | 2008-02-20 | Novartis AG | Purinderivate als A2a Agonisten |
| EP1903044A1 (de) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosinderivate als Agonisten des A2A-Rezeptors |
| JP2010508835A (ja) * | 2006-11-10 | 2010-03-25 | ノバルティス アーゲー | シクロペンテンジオールモノアセテート誘導体 |
| US20110144156A1 (en) * | 2008-08-19 | 2011-06-16 | Universiteit Leiden | A3 adenosine receptor allosteric modulators |
| WO2010134067A1 (en) * | 2009-05-17 | 2010-11-25 | Can-Fite Biopharma Ltd. | A3 adenosine receptor agonists for the reduction of intraocular pressure |
| MX378538B (es) * | 2012-08-09 | 2025-03-10 | Can Fite Biopharma Ltd | Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual. |
| CN103992310B (zh) * | 2013-05-14 | 2016-07-06 | 中国医学科学院医药生物技术研究所 | 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用 |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| IL242723B (en) | 2015-11-23 | 2019-12-31 | Can Fite Biopharma Ltd | A3 adenosine receptor ligand for the treatment of ectopic fat accumulation |
| EP3445761A1 (de) * | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3-modulatoren |
| ES2676535B1 (es) | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| IL254535A0 (en) | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | Adenosine a3 receptor ligand for use in the management of cytokine release syndrome |
| IL264112A (en) | 2019-01-06 | 2020-07-30 | Fishman Pnina | An a3 adenosine receptor ligand for use for reducing level of adipocytes |
| EP4499641A1 (de) * | 2022-03-29 | 2025-02-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | A3-adenosinrezeptor-positive allosterische modulatoren |
| WO2024014851A1 (ko) * | 2022-07-12 | 2024-01-18 | 주식회사 넥스트젠바이오사이언스 | Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물 |
| IL300132A (en) * | 2023-01-23 | 2024-08-01 | Can Fite Biopharma Ltd | Pancreatic cancer treatment |
| IT202300014340A1 (it) | 2023-07-10 | 2025-01-10 | Consiglio Nazionale Ricerche | Trattamento di malattie associate alla disfunzione del gene ocrl. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960007566A (ko) | 1994-08-19 | 1996-03-22 | 김정규 | 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도 |
| KR20010030891A (ko) * | 1997-10-03 | 2001-04-16 | 마크로메드 인코퍼레이션 | 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체 |
| WO2002062801A1 (en) * | 2001-02-05 | 2002-08-15 | Otsuka Pharmaceutical Factory, Inc. | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension |
| US20020179549A1 (en) * | 2001-06-04 | 2002-12-05 | Chris Felcman | System and method for mounting a keyboard and display assembly in a 1U rack space |
| US20040137477A1 (en) * | 2002-10-22 | 2004-07-15 | Can-Fite Biopharma, Ltd. | A3AR as a marker for a diseased state |
| EP1699459B1 (de) | 2003-12-29 | 2007-06-06 | Can-Fite Biopharma Ltd. | Verfahren zur behandlung von multipler sklerose |
| CN101083998A (zh) * | 2004-11-22 | 2007-12-05 | 王者制药研究发展有限公司 | 用腺苷a3受体激动剂强化治疗hif－1介导的病症 |
| DK1983990T3 (da) | 2006-01-26 | 2011-07-11 | Us Gov Health & Human Serv | Allosteriske A3-adenosin-receptormodulatorer |
-
2007
- 2007-01-25 DK DK07763034.1T patent/DK1983990T3/da active
- 2007-01-25 DE DE602007013359T patent/DE602007013359D1/de active Active
- 2007-01-25 WO PCT/US2007/001930 patent/WO2007089507A1/en not_active Ceased
- 2007-01-25 JP JP2008552392A patent/JP5414277B2/ja active Active
- 2007-01-25 ES ES07763034T patent/ES2360632T3/es active Active
- 2007-01-25 CN CN2007800106767A patent/CN101410114B/zh active Active
- 2007-01-25 AT AT07763034T patent/ATE502640T1/de active
- 2007-01-25 KR KR1020087020924A patent/KR101383228B1/ko active Active
- 2007-01-25 EP EP07763034A patent/EP1983990B1/de active Active
-
2008
- 2008-07-28 US US12/219,772 patent/US8420664B2/en active Active
-
2013
- 2013-03-13 US US13/800,560 patent/US9326978B2/en active Active
- 2013-09-18 JP JP2013192745A patent/JP2013253108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013253108A (ja) | 2013-12-19 |
| DK1983990T3 (da) | 2011-07-11 |
| JP2009524668A (ja) | 2009-07-02 |
| WO2007089507A1 (en) | 2007-08-09 |
| US20090054476A1 (en) | 2009-02-26 |
| EP1983990A1 (de) | 2008-10-29 |
| JP5414277B2 (ja) | 2014-02-12 |
| CN101410114B (zh) | 2012-07-04 |
| KR101383228B1 (ko) | 2014-04-09 |
| US8420664B2 (en) | 2013-04-16 |
| US9326978B2 (en) | 2016-05-03 |
| DE602007013359D1 (de) | 2011-05-05 |
| KR20080099855A (ko) | 2008-11-13 |
| US20130197025A1 (en) | 2013-08-01 |
| CN101410114A (zh) | 2009-04-15 |
| ES2360632T3 (es) | 2011-06-07 |
| EP1983990B1 (de) | 2011-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1983990T3 (da) | Allosteriske A3-adenosin-receptormodulatorer | |
| UA94600C2 (en) | Indole sulfonamide modulators of progesterone receptors | |
| MX2009013832A (es) | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. | |
| HN2010002774A (es) | DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| DK1768625T3 (da) | Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer | |
| CY1108794T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| WO2007062078A3 (en) | Thrombopoietin activity modulating compounds and methods | |
| MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| BR0110767A (pt) | Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| CR9022A (es) | Derivados de sulfonamida novedosos como moduladores de receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| BRPI0513677B8 (pt) | derivados de pirrol como agentes farmacêuticos | |
| ZA200801732B (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
| EA201692167A1 (ru) | Модуляторы толл-подобных рецепторов | |
| BRPI0410418A (pt) | fenil quinolinas e seu uso como moduladores do receptor de estrogênio | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| EA201071288A1 (ru) | Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина | |
| WO2008118141A3 (en) | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy | |
| MA32150B1 (fr) | Inhibiteurs heterocycliques de la stearoyl-coa desaturase | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| WO2006050058A3 (en) | Methods of detection and therapy of inflamed tissues using immune modulation | |
| MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
| BRPI0510126A (pt) | derivados de piperidina como moduladores do receptor de quimiocina ccr5 | |
| BRPI0517259A (pt) | novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1983990 Country of ref document: EP |